RSS-Feed abonnieren
DOI: 10.1055/s-2005-861326
Die Psoriasistherapie in der dermatologischen Praxis führt zu verbesserter Lebensqualität - Ergebnisse einer naturalistischen Multizenter-Studie
Psoriasis Treatment in Dermatological Practice Improves Quality of Life - Results of a Naturalistic Multi-Centre StudyPublikationsverlauf
Publikationsdatum:
15. Juli 2005 (online)
![](https://www.thieme-connect.de/media/derma/200507/lookinside/thumbnails/10.1055-s-2005-861326-1.jpg)
Zusammenfassung
Hintergrund: Die Psoriasis vulgaris geht mit erheblichen Einbußen der gesundheitsbezogenen Lebensqualität (LQ) einher. Nur wenige Untersuchungen liegen bislang zur Frage der Wirksamkeit einer dermatologischen Standard-Therapie unter Praxis-Bedingungen vor. Zielsetzung: Erhebung der LQ einer bundesweiten Stichprobe ambulanter Patienten mit Psoriasis vulgaris im Verlaufe der Therapie unter Praxisbedingungen. Methodik: Prospektive, multizentrische LQ-Studie in dermatologischen Praxen und Polikliniken an ambulanten erwachsenen Patienten mit chronischer Plaque-Psoriasis mittlerer oder schwerer Ausprägung. Für die Therapie der Psoriasis wurden keine Vorgaben gemacht. Die Erhebung der LQ erfolgte anhand des Dermatology Life Quality Index (DLQI), des EQ-5D und der EQ-5D visuellen Analogskala (VAS). Ergebnisse: Der mittlere DLQI-Summenscore war mit 8,9 deutlich erhöht. Die Einschränkungen betrafen insbesondere die Bereiche Schmerzen/körperliche Beschwerden und Angst/Niedergeschlagenheit. Der Befall sichtbarer Körperareale wie des Gesichtes sowie der Genitalien ging mit eingeschränkterer Lebensqualität einher. Sechs Wochen nach der ersten Konsultation zeigte sich eine Besserung der Lebensqualität in allen Bereichen. Im gleichen Zeitraum kam es zu einer selbst eingeschätzten Besserung der Psoriasis bezüglich der klinischen Symptome. Im EQ-5D fanden sich gleichfalls Besserungen der Befindlichkeit. Schlussfolgerungen: Die qualifizierte dermatologische Behandlung der Psoriasis unter Praxisbedingungen geht bei mittelschweren und schweren Formen der Psoriasis mit signifikanten Verbesserungen der LQ einher.
Abstract
Background: Psoriasis vulgaris is associated with severe reductions of health-related quality of life (QoL). There are few investigations adressing the efficacy of dermatological standard treatment under practice conditions. Objective: Evaluation of the QoL in a nationwide out-patient sample of patients with psoriasis vulgaris in the course of treatment under practice conditions. Methods: Prospective, multicenter QoL study in dermatologic practices and outpatient services on adult patients with chronic plaque psoriasis of moderate or severe degree. There were no regulations for treatment. QoL was evaluated using the Dermatology Life Quality Index (DLQI), the EQ-5D and EQ-5D visual analogue scale (VAS). Results: The average DLQI total score was markedly increased at 8,9. Limitations in QoL were especially due to pain/physical trouble and to anxiety/depression. Especially patients with sensitive skin areas affected (face or genital region) showed impairment of Qol. Six weeks after the first consultation QoL had markedly improved. In the same period, the psoriasis improved clinically, as assessed by the global patient assessment. Conclusions: Qualified dermatological treatment of moderate to severe psoriasis under practice conditions leads to signficant improvements of QoL.
Literatur
- 1 Arikian S R, Einarson T R. The annual cost of psoriasis. J Am Acad Dermatol. 1994; 30 (6) 1047-1048
- 2 Augustin M, Zschocke I, Lange S, Seidenglanz K, Amon U. Lebensqualität bei Hauterkrankungen: Vergleich verschiedener Lebensqualitäts-Fragebogen bei Psoriasis und atopischer Dermatitis. Hautarzt. 1999; 50 715-722
- 3 Augustin M, Zschocke I, Seidenglanz K, Lange S, Schiffler A, Amon U. Validation and clinical results of the FLQA-d, a quality of life questionnaire for patients with chronic skin diseases. Dermatol Psychosom. 2000; 1 12-17
- 4 Augustin M. Erfassung von Lebensqualität in dermatologischen Studien. Leitlinie der Subkommission „Pharmako-Ökonomie und Lebensqualität” der DDG. Hautarzt. 1999; 52 697-700
- 5 Bullinger M. Gesundheitsbezogene Lebensqualität und subjektive Gesundheit. Überblick über den Stand der Forschung zu einem neuen Evaluationskriterium in der Medizin. PPmP. 1997; 47 76-91
- 6 Carey W, Gulliver W P. Efalizumab therapy improves and sustains health-related quality of life in patients with moderate to severe plaque psoriasis. JEADV. 2004; 17 (suppl. 3) 371-372
- 7 Caro I, Woolley J M, Zitnik R J. Effects of etanercept therapy on the health-related quality of life of subjects with moderate to severe psoriasis. JEADV. 2003; 17 (suppl. 3) 140
- 8 Chren M, Lasker R J, Quinn L M, Mostow E N, Zyzanski S J. Skindex, a Quality-of-Life measure for patients with skin diseases: reliability, validity and responsibeness. J Invest Dermatol. 1996; 107 707-713
- 9 De Arruda L H, De Moraes A P. The impact of psoriasis on quality of life. Br J Dermatol. 2001; 144 (suppl. 58) 33-36 [Review]
- 10 Ellis C N, Mordin M M, Adler E Y. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003; 4 (2) 131-139
- 11 Feldman S R, Fleischer A B Jr, Reboussin D M, Rapp S R, Bradham D D, Exum M L, Clark A R. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol. 1997; 37 (4) 564-569
- 12 Finlay A Y, Kahn G K. Dermatology life quality index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19 210-216
- 13 Fredriksson T, Pettersson U. Severe Psoriasis - Oral Therapy with a new Retinoid. Dermatologica. 1978; 157 238-244
- 14 Galadari I, Rigel E, Lebwohl M. The cost of psoriasis treatment. J Eur Acad Dermatol Venereol. 2001; 15 (4) 290-291
-
15 Greiner W, Uber A.
Gesundheitsökonomische Studien und der Einsatz von Lebensqualitätsindices am Beispiel des LQ-Indexes EQ-5D (EuroQol). In: Ravens-Sieberer U, Cieza A Lebensqualität und Gesundheitsökonomie in der Medizin. ecomed Verlagsgesellschaft,. 2001: S 336-351 - 16 Gupta M A, Gupta A K. Quality of life of psoriasis patients. J Eur Acad Dermatol Venereol. 2000; 14 (4) 241-242
- 17 Javitz H S, Ward M M, Farber E, Nail L, Vallow S G. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002; 46 (6) 850-860
- 18 Jenner N, Campell J, Plunkett A, Marks R. Cost of psoriasis: a study on the morbidity and financial effects of having psoriasis in Australia. Australas J Dermatol. 2002; 43 (4) 255-261
-
19 Juniper E F, Guyatt G H, Jaeschke R.
How to develop and validate a new health-related quality of life instrument. In: Spilker B (ed) Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven Philadelphia 1996: 49-56 - 20 Krueger G, Koo J, Lebwohl M, Menter A, Stern R S, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001; 137 (3) 280-284
- 21 Krueger G G, Feldman S R, Camisa C, Duvic M, Elder J T, Gottlieb A B, Koo J, Krueger J G, Lebwohl M, Lowe N, Menter A, Morison W L, Prystowsky J H, Shupack J L, Taylor J R, Weinstein G D, Barton T L, Rolstad T, Day R M. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?. J Am Acad Dermatol. 2001; 43 (2 Pt 1) 281-285
- 22 Krueger G G, Papp K A, Strough D B, Loven K H, Gulliver W P, Ellis C N. A randomised, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002; 47 (6) 821-833
- 23 Lange S, Zschocke I, Langhardt S, Amon U, Augustin M. Effekte kombinierter dermatologischer und verhaltensmedizinischer Maßnahmen bei stationären Patienten mit Psoriasis und atopischer Dermatitis. Hautarzt. 1999; 50 791-797
- 24 Lange S, Zschocke I, Seidenglanz K, Schiffler A, Zöllinger A, Amon U, Augustin M. Predictors of the Quality of Life in Patient with Atopic Dermatitis. Dermatol Psychosom. 1999; 1 66-70
- 25 Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol. 2000; 80 (6) 430-434
- 26 McKenna K E, Stern R S. The Impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J Am Acad Dermatol. 1997; 36 (3Pt1) 388-394
- 27 Rapp S R, Cottrell C A, Leary M R. Social coping strategies associated with quality of life decrements among psoriasis patients. Br J Dermatol. 2001; 145 (4) 610-616
- 28 Richards H L, Fortune D G, O'Sullivan T M, Main C J, Griffiths C E. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999; 41 (4) 581-583
- 29 Sackett D L, Chambers L W, MacPherson A S, Goldsmith C H, McAuley R G. The development and application of indices of health: general methods and summary of results. Am J Public Health. 1977; 67 423-428
- 30 Salek M S, Finlay A Y, Luscombe D K. et al . Cyclosporin improves quality of life in psoriasis - does this matter?. Br J Dermatol. 1993; 129 (suppl. 42) 32
-
31 Sartorius N.
A WHO-method for the assessment of health-related quality of life (WHO-QOL). In: Walker S, Rosser M (eds) Quality of life assessment: key issues in the 1990's. Dordrecht; Kluwer 1993: 201-203 - 32 Touw C R, Jakkaart-Van Roijen L, Verboom P, Paul C, Rutten F F, Finlay A Y. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol. 2001; 144 (5) 967-972
-
33 Traupe H, Robra B.
Gesundheitsberichterstattung des Bundes . Heft 11 Psoriasis. Robert Koch-Institut Berlin 2002 - 34 Vardy D, Besser A, Amir M, Gesthalter B, Biton A, Buskila D. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol. 2002; 147 (4) 736-742
- 35 Vensel E, Hillex T, Trent J, Taylor J R, Kirsner R S, Kerdel F A, Taylor J R, Schwartzberg J B. Sustained improvement of the quality of life of patients with psoriasis after hospitalization. J Am Acad Dermatol. 2000; 43 (5 Pt 1) 858-860
- 36 Wall A RJ, Poyner T F, Menday A P. A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis. Br J Dermatol. 1998; 139 1005-1011
- 37 Weiss S C, Kimball A B, Liewehr D J, Blauvelt A, Turner M L, Emanuel E J. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002; 4 512-518
- 38 Zachariae H, Zachariae R, Blomqvist K, Davidsson S, Molin L, Mork C, Sigurgeirsson B. Quality of life and prevalence of arthritis reported by 5.795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol. 2002; 82 (2) 108-113
- 39 Feldman S R. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat. 2004 Jan; 15 (1) 27-29
- 40 Krueger G G, Feldman S R, Camisa C, Duvic M, Elder J T, Gottlieb A B, Koo J, Krueger J G, Lebwohl M, Lowe N, Menter A, Morison W L, Prystowsky J H, Shupack J L, Taylor J R, Weinstein G D, Barton T L, Rolstad T, Day R M. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?. J Am Acad Dermatol. 2000 Aug; 43 (2 Pt 1) 281-285
Univ.-Prof. Dr. Matthias Augustin
FG Gesundheitsökonomie und Lebensqualitätsforschung · Klinik für Dermatologie und Venerologie · Univ.-Klinikum HH Eppendorf
Martinistraße 52 · 20246 Hamburg ·
eMail: m.augustin@uke.uni-hamburg.de